实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (3): 422-425.doi: 10.3969/j.issn.1672-5069.2025.03.026

• 肝硬化 • 上一篇    下一篇

内镜曲张静脉套扎术联合生长抑素和奥美拉唑治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究*

蒋召芹, 宋洁, 穆永芳   

  1. 066000 河北省秦皇岛市第一医院急诊科(蒋召芹,穆永芳);华北理工大学附属医院急诊科(宋洁)
  • 收稿日期:2024-12-27 发布日期:2025-05-14
  • 作者简介:蒋召芹,女,41岁,医学硕士,副主任医师。E-mail:jiangzhaoqin@163.com
  • 基金资助:
    *河北省卫生健康委科研项目(编号:20224238)

Efficacy of endoscopic variceal ligation with combination of intravenous administration of somatostatin and omeprazole in the treatment of liver cirrhosis patients with esophagogastric variceal bleeding

Jiang Zhaoqin, Song Jie, Mu Yongfang   

  1. Department of Emergency, First Hospital, Qinhuangdao 066000, Hebei Province, China
  • Received:2024-12-27 Published:2025-05-14

摘要: 目的 观察内镜曲张静脉套扎术(EVL)联合生长抑素和奥美拉唑治疗肝硬化并发食管胃底静脉曲张破裂出血(EVB)患者的疗效。方法 2020年1月~2023年1月我院收治的肝硬化并发EVB患者103例,被随机分为对照组51例和观察组52例,给予所有患者奥美拉唑联合生长抑素治疗,观察组在此治疗的基础上行EVL治疗,随访6个月。使用彩色多普勒超声诊断仪检测门静脉和脾静脉内径及其血流量。结果 在急性期,观察组死亡3例(5.8%),对照组死亡8例(15.7%);49例观察组生存患者输血量、止血时间和住院时间分别为(406.5±138.1)mL、(1.6±0.7)d和(5.8±1.5)d,显著少于或短于43例对照组生存者【分别为(615.7±240.3)mL、(4.1±0.5)d和(9.1±1.7)d,P<0.05】;治疗后,观察组血清白蛋白水平为(33.4±5.3)g/L,显著高于对照组【(31.3±4.6)g/L,P<0.05】;观察组血清纤维蛋白原水平为(4.2±0.5)g/L,显著高于对照组【(3.8±0.4)g/L,P<0.05】;观察组外周血PLT计数、血细胞比容和血红蛋白水平分别为(219.3±20.1)×109/L、(36.4±4.2)%和(109.6±6.1)g/L,均显著高于对照组【分别为(176.2±19.5)×109/L、(31.7±4.3)%和(91.2±7.0)g/L,P<0.05】;两组门静脉和脾静脉内径和血流量比较,无显著性差异(P>0.05);随访半年,观察组发生再出血1例(2.0%),救治后出血止,对照组发生再出血3例(7.0%),其中死亡1例(2.3%)。结论 采用EVL联合生长抑素和奥美拉唑治疗肝硬化并发EVB患者止血效果好,降低急性期病死率,具有很大的临床实用意义。

关键词: 肝硬化, 食管胃底静脉曲张破裂出血, 内镜曲张静脉套扎术, 生长抑素, 奥美拉唑, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of endoscopic variceal ligation (EVL) with intravenously administered somatostatin and omeprazole in the treatment of liver cirrhosispatients complicated withesophagogastric variceal bleeding (EVB). Methods 103 patients with liver cirrhosisand EVB were encountered in our hospital between January 2020 and January 2023, and were randomly divided into control (n=51) and observation (n=52) group. All patients in the two groups underwent EVL, and those in the observation were given intravenously omeprazole and somatostatin for 3 to 5 days until hemostasis, and all were followed-up for six months. Diameter and venous flow of portal vein and splenic vein were measured by color Doppler ultrasonography. Results Three patients (5.8%) in the observation group and eight patients (15.7%) in the control group died of emergent bleeding; blood transfusion volume, hemostasis time and hospitalization days in 49 survivals in the observation were (406.5±138.1)mL, (1.6±0.7)d and (5.8±1.5)d, much less or shorter than [(615.7±240.3)mL, (4.1±0.5)d and (9.1±1.7)d, respectively, P<0.05] in 43 survivals in the control; after treatment, serum albumin level in the observation was (33.4±5.3)g/L, much higher than [(31.3±4.6)g/L, P<0.05], and serum fibrinogen level was (4.2±0.5)g/L, much higher than [(3.8±0.4)g/L, P<0.05] in the control; peripheral blood platelet count, hematocrit and hemoglobin levels in the observation group were(219.3±20.1)×109/L, (36.4±4.2)% and (109.6±6.1)g/L, all much higher than [(176.2±19.5)×109/L, (31.7±4.3)% and (91.2±7.0)g/L, respectively, P<0.05] in the control; there were no significant differences as respect to diameters and blood flow of portal vein and splenic vein in the two groups (P>0.05); by end of six month follow-up, re-bleeding occurred in one patient (2.0%)in the observation group and survived, and it occurred in three patients (7.0%)in the control, and one (2.3%)of them died. Conclusion EVL and intravenous administration of somatostatin and omeprazole in dealing with patients with EVB is efficacious, which could stop intragastric bleeding definitely and effectively, and warrants further clinical investigation.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding , Endoscopic variceal ligation, Somatostatin, Omeprazole, Therapy